Statements

The aim of the Consensus Recommendations for the Use of Immunoglobulin Replacement Therapy in Immune Deficiency is to support immunologists and other clinicians in their use of immunoglobulin products in clinical practice. The consensus document provides practical recommendations on:

  • evaluation of humoral immune responses in patients
  • when to consider the diagnosis of antibody deficiency
  • indications for immunoglobulin replacement therapy in primary as well as secondary antibody deficiency
  • appropriate administration and monitoring of immunoglobulin replacement therapy
  • adverse effects associated with immunoglobulin replacement therapy.

These consensus recommendations have been produced from evidence based literature and expert opinion.  As knowledge about and experience with immunoglobulin replacement therapy increase, revision of clinical practice will be required.  It is the intention of the authors to update these recommendations annually, or as the need arises.  The most recent version of the consensus recommendations will be available from this website and can be downloaded here:
PDF Icon APIIEG Consensus Recommendations Edition 2 Jul 2009 (0.7MB)

The Consensus Recommendations for the Use of Immunoglobulin Replacement Therapy in Immune Deficiency were reviewed by the Australasian Society of Clinical Immunology and Allergy (ASCIA) and endorsed by the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) during June 2008.

Copyright Asia Pacific Immunoglobulins in Immunology Expert Group Inc.

Apart from any fair dealing for the use of private study, research, criticism, or review as permitted under the Copyright Act, no part of this book may be transmitted or reproduced in any form, electronic or mechanical, or by any information storage and retrieval system, without the written permission of the publishers.

This publication has been made possible by an undirected educational grant from CSL Biotherapies.

Waiver of liability

The information contained in this document is intended to serve as a guideline only. Neither the contributing authors nor the Asia Pacific Immunoglobulins in Immunology Expert Group shall be liable for any actions, claims, damages, costs or obligations that may arise from the inappropriate use or misuse of the material contained in this document.

STATEMENTS